Shahzad Malik

Shahzad joined Advent in 1999 with a strong background in science, clinical medicine, and international finance.

He gained an MA in Physiological Sciences from Oxford University and an MD from Cambridge University, after which he specialised in interventional cardiology while also pursuing clinical and fundamental scientific research in heart muscle disorders.

Since joining Advent, Shahzad has been actively involved in over 25 portfolio companies in Europe and the USA in all sectors of Life Sciences, including Algeta, Respivert, Biocartis and Axonics Modulation Technologies.

Shahzad currently serves on the Board of several portfolio companies, including Acutus Medical, GMP-Orphan, and Nalu Medical.